Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma
| Autor: | Brittany E. Givens, Aliasger K. Salem, Sean M. Geary |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Hypersensitivity
Immediate 0301 basic medicine CpG Oligodeoxynucleotide Immunology Drug Evaluation Preclinical Review Self assembled 03 medical and health sciences Th2 Cells 0302 clinical medicine CPG-oligonucleotide Immune system immune system diseases Hypersensitivity medicine Animals Humans Immunology and Allergy Asthma Clinical Trials as Topic business.industry hemic and immune systems Allergic asthma Th1 Cells respiratory system medicine.disease respiratory tract diseases Clinical trial 030104 developmental biology Oligodeoxyribonucleotides 030228 respiratory system Oncology Cytokines Nanoparticles ALLERGEN EXPOSURE business |
| Zdroj: | Immunotherapy. 10:595-604 |
| ISSN: | 1750-7448 1750-743X |
| Popis: | Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|